載入中
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
前收盤價
US$1.21
+US$0.04 · +3.42%
盤中時間採用ET。市場資料可能有所延遲。
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
日內區間
目前US$1.21
52週區間
目前US$1.21
盤中時間採用ET。市場資料可能有所延遲。
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
日內區間
目前US$1.21
52週區間
目前US$1.21
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 2521.56萬 USD | 1999.54萬 USD | 3879.06萬 USD | 1651.55萬 USD | 847.9萬 USD |
| 銷售、一般及管理費用 | 447.97萬 USD | 669.95萬 USD | 624.44萬 USD | 899.57萬 USD | 605.82萬 USD |
| 營業費用 | 2969.53萬 USD | 2669.49萬 USD | 4503.5萬 USD | 2551.13萬 USD | 1453.72萬 USD |
| 利息收入 | 69.91萬 USD | 33.18萬 USD | 66.79萬 USD | 18.27萬 USD | 1.33萬 USD |
| 利息支出 | — | 185.32萬 USD | — | — | — |
| 營業利益 | −2969.53萬 USD | −2669.49萬 USD | −4503.5萬 USD | −2551.13萬 USD | −1453.72萬 USD |
| 淨利 | −2885.42萬 USD | −2459.04萬 USD | −5620.4萬 USD | −2532.86萬 USD | −1448.71萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$25.67
上漲空間 2021.49%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI209.79萬0.00%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF58.65萬0.00%954億 USD0.05%US$235+0.80%
iShares Micro-Cap ETFIWC11.45萬0.01%13.17億 USD0.60%US$183+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM4萬0.03%1.17億 USD0.73%US$15.9402+0.25%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
